Ginkgo Bioworks (DNA) Projected to Post Earnings on Tuesday

Ginkgo Bioworks (NYSE:DNA) will likely be announcing its Q4 2025 results before the market opens on Tuesday, February 24th. Analysts expect the company to announce earnings of ($1.80) per share for the quarter. Interested persons can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Tuesday, February 24, 2026 at 5:30 PM ET.

Ginkgo Bioworks Price Performance

DNA stock opened at $9.33 on Tuesday. The stock has a market capitalization of $565.00 million, a price-to-earnings ratio of -1.50 and a beta of 1.55. The company has a 50-day moving average of $9.14 and a two-hundred day moving average of $10.80. Ginkgo Bioworks has a 52-week low of $5.00 and a 52-week high of $17.58.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the company. TD Cowen decreased their target price on Ginkgo Bioworks from $14.00 to $12.00 and set a “buy” rating for the company in a research note on Thursday, January 8th. Wall Street Zen lowered Ginkgo Bioworks from a “hold” rating to a “sell” rating in a report on Saturday, November 8th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Ginkgo Bioworks in a research report on Wednesday, January 21st. One research analyst has rated the stock with a Buy rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Reduce” and an average target price of $10.50.

Institutional Trading of Ginkgo Bioworks

Several institutional investors have recently modified their holdings of DNA. Shay Capital LLC increased its position in shares of Ginkgo Bioworks by 6.2% during the second quarter. Shay Capital LLC now owns 19,382 shares of the company’s stock valued at $218,000 after purchasing an additional 1,124 shares during the period. Deutsche Bank AG boosted its stake in Ginkgo Bioworks by 3.5% during the fourth quarter. Deutsche Bank AG now owns 35,689 shares of the company’s stock worth $297,000 after buying an additional 1,207 shares in the last quarter. Quarry LP bought a new stake in Ginkgo Bioworks in the 3rd quarter valued at $29,000. Verition Fund Management LLC raised its stake in shares of Ginkgo Bioworks by 2.4% in the 3rd quarter. Verition Fund Management LLC now owns 96,419 shares of the company’s stock valued at $1,406,000 after buying an additional 2,265 shares in the last quarter. Finally, California State Teachers Retirement System boosted its position in shares of Ginkgo Bioworks by 10.0% during the 2nd quarter. California State Teachers Retirement System now owns 26,674 shares of the company’s stock valued at $300,000 after acquiring an additional 2,426 shares in the last quarter. Institutional investors and hedge funds own 78.63% of the company’s stock.

About Ginkgo Bioworks

Ginkgo Bioworks, Inc is a synthetic biology company that designs custom microbes for customers across a range of industries. Utilizing a proprietary organism foundry platform, the company engineers cells to produce high-value chemicals, enzymes, and other biological materials. By integrating automation, data analytics and machine learning, Ginkgo Bioworks seeks to accelerate the development of biologically derived solutions at industrial scale.

The company’s services span the entire development cycle, from genetic design and strain optimization to fermentation and downstream processing.